Cell & Gene

As monoclonal antibody production scales, conventional two-stage depth filtration can create significant facility and workflow challenges. Higher harvest volumes and cell densities often require more filters, increasing footprint demands and complicating operations. For volumes above 2,000 L, single-use centrifugation can replace primary depth filtration, reducing the number of clarifying filters needed while preparing the harvest stream for downstream purification.

BE BioSol is the biologics CDMO business of Biological E. Limited, combining more than 70 years of biopharmaceutical manufacturing experience with a growing, integrated development and manufacturing platform for global biopharma partners. With a strong track record supporting regulated markets and long-standing relationships with leading pharmaceutical companies, BE BioSol provides development, analytical, technology transfer, and commercial manufacturing solutions across biologics and vaccines.

Successful viral vector scale‑up depends on early process design, predictive models, and execution strategies that anticipate GMP realities rather than simply increasing production volume. Adenoviruses are being reimagined as powerful tools for oncolytic cancer therapy, using their immunogenicity, tumor selectivity, and synergy with immunotherapy to drive new clinical progress.

By Sid Kerkar, MD, Founder and CEO, AllerGene AI Therapeutics My interest in applying CAR T cell therapy to allergic disease began at home. All three of my children were diagnosed with severe, life-threatening allergies, turning a disease I understood as a physician-scientist into something deeply personal.

Get more Cell & Gene insight with our FREE newsletter Newsletter | September 4, 2026 The evidence gap in Hematology: From trial endpoints to patient outcomes As hematology trials become more complex, sponsors face increasing pressure to accelerate development while generating stronger evidence, mitigating recruitment risk and supporting faster patient access.

Introducing our solution for commercial-scale DPI blister filling. Achieve accurate, clean, scalable powder dosing with our DPI Blister Filler, designed for commercial pharmaceutical manufacturing. Ideal for Dry powder inhaler (DPI) filling. Pharmaceutical teams working with magnesium stearate-based formulations. Commercial blister strip production. CDMOs requiring scalable blister filling technology.

Webinar: Beyond the Starting Material: Building a Path to GMP Manufacturing Success Cell therapy manufacturing success starts long before the GMP cleanroom. Join experts from New York Blood Center Enterprises’ Comprehensive Cell Solutions (CCS) team to explore how starting material sourcing, collection strategies, process development, and technology transfer shape manufacturing outcomes.

Managing outsourced programs shouldn't mean dealing with fragmented spreadsheets and endless email chains to see where your project stands. By unifying your data into a single digital platform, you bring clear visibility to your programs for confident, informed decisions. Building a multi-product ATMP facility? Master the HVAC configuration, contamination controls, and N+1 redundancy an operations-first approach demands. Connect with facility experts and plan your next expansion with confidence.

By Zachary Roberts, MD, Ph.D., president and chief executive officer, Allogene Therapeutics In large B-cell lymphoma (LBCL), treatment decisions have traditionally been driven by disease that is clinically apparent through scans, biopsies and symptoms. Blood tests, enabling molecular detection of cancer, have the potential to change that paradigm.

The AAV gene therapy field is moving beyond reliance on a small number of naturally occurring serotypes toward engineered capsids designed for specific tissues, routes of administration, and therapeutic objectives. Rational design, directed evolution, and computational approaches are expanding the available vector toolbox and creating opportunities to improve tissue specificity, reduce effective doses, and potentially ease manufacturing demands.